文献速递眼底病与葡萄膜炎

溴莫尼定和生长抑素局部治疗导致早期糖尿病视网膜病变患者视网膜血管扩张:EUROCONDOR研究

Topical Treatment With Brimonidine and Somatostatin Causes Retinal Vascular Dilation in Patients With Early Diabetic Retinopathy From the EUROCONDOR.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2019-01-01

本研究为96周前瞻性欧洲多中心II至III期试验,将无或早期糖尿病视网膜病变的2型糖尿病患者按1:1:1随机分配至安慰剂、溴莫尼定或生长抑素局部治疗。在基线为轻度糖尿病视网膜病变的患者中,与安慰剂组相比,溴莫尼定和生长抑素组出现视网膜小动脉和小静脉扩张。

要点

  • 在基线轻度糖尿病视网膜病变患者中,溴莫尼定组视网膜小动脉管径增加+6.2 μm(P=0.006),生长抑素组增加+7.2 μm(P=0.006)。
  • 在基线轻度糖尿病视网膜病变患者中,溴莫尼定组视网膜小静脉管径增加+13.9 μm(P=0.01),生长抑素组增加+14.3 μm(P=0.0001)。
  • 在基线无或极轻度糖尿病视网膜病变患者中,未观察到上述血管管径变化。

核心结论

  • 溴莫尼定和生长抑素局部治疗导致已有早期糖尿病视网膜病变的2型糖尿病患者视网膜小动脉和小静脉扩张。

研究设计与样本

  • 96周前瞻性欧洲多中心II至III期试验,将无或早期糖尿病视网膜病变的2型糖尿病患者按1:1:1随机分配至安慰剂、溴莫尼定或生长抑素局部治疗。

主要发现

  • 449例患者中297例完成研究且视网膜图像可分级,中位年龄64.5岁,中位糖尿病病程9.9年,65.7%为男性。
  • 基线时Early Treatment Diabetic Retinopathy Study分级为10(无糖尿病视网膜病变,42.8%)、20(极轻度糖尿病视网膜病变,28.3%)和35(轻度糖尿病视网膜病变,29.0%),各组间CRAE和CRVE无差异。
  • 与基线无或极轻度糖尿病视网膜病变患者不同,基线轻度糖尿病视网膜病变患者中,活性治疗组较安慰剂组出现更大的视网膜小动脉管径(溴莫尼定:+6.2 μm,P=0.006;生长抑素:+7.2 μm,P=0.006)。
  • 基线轻度糖尿病视网膜病变患者中,活性治疗组较安慰剂组出现更大的视网膜小静脉管径(溴莫尼定:+13.9 μm,P=0.01;生长抑素:+14.3 μm,P=0.0001)。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Structural retinal microvascular changes have been identified as risk markers of diabetic retinopathy (DR). In order to estimate the retinal response of neuroprotective eye drops, we aimed to evaluate the effect of topical retinal neuroprotection on retinal microvascular changes in early DR. METHODS: Patients with type 2 diabetes with no or early DR were randomized 1:1:1 to topical treatment with placebo, brimonidine, or somatostatin in a 96-week prospective, phase II to III, European multicenter trial. Retinal vascular calibers were measured semiautomatically in digital fundus images by certified graders at baseline and follow-up and summarized as central retinal arteriolar and venular equivalent (CRAE and CRVE). RESULTS: Of 449 patients originally included, 297 completed the study with gradable retinal images. Median age and duration of diabetes was 64.5 and 9.9 years, and 65.7% were male. At baseline, Early Treatment Diabetic Retinopathy Study levels were 10 (no DR, 42.8%), 20 (minimal DR, 28.3%), and 35 (mild DR, 29.0%), and CRAE and CRVE did not differ between groups. As opposed to patients with no or minimal DR at baseline, patients with mild DR in the active groups developed a larger retinal arteriolar (brimonidine: +6.2 μm, P = 0.006; somatostatin: +7.2 μm, P = 0.006) and venular (brimonidine: +13.9 μm, P = 0.01; somatostatin: +14.3 μm, P = 0.0001) caliber in contrast to those in the placebo group. CONCLUSIONS: Topical treatment with brimonidine and somatostatin causes retinal arteriolar and venular dilation in patients with type 2 diabetes and preexisting early DR. Upcoming studies should elaborate on the potential of these findings in arresting early DR.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Grauslund J, Frydkjaer-Olsen U, Peto T, et al. Topical Treatment With Brimonidine and Somatostatin Causes Retinal Vascular Dilation in Patients With Early Diabetic Retinopathy From the EUROCONDOR. Invest Ophthalmol Vis Sci. 2019. PMID: 31112610. doi:10.1167/iovs.18-26487

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。